Immunex Enbrel Psoriatic Arthritis Advisory Cmte. Expected In December
Executive Summary
Immunex expects the supplemental application for Enbrel in psoriatic arthritis to be reviewed by FDA's Arthritis Advisory Committee in December.
You may also be interested in...
Immunex Enbrel Building Sales Force For Psoriatic Arthritis Approval
Immunex is building its first internal Enbrel sales force in preparation for etanercept's sBLA approval for psoriatic arthritis, Commercial Operations General Manager Mark Booth announced Aug. 20 during the company's R&D update in Seattle.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials